Evidence map›Paper›PMID 41677989›Full record

ArticleNeurogenetics2026

Probable cerebral amyloid angiopathy - related inflammation in a 32-year-old woman with down syndrome.

Thales Pardini Fagundes, Gustavo Maximiano Alves, Mateus Gustavo Favaro, Joyce Yuri Silvestre Yamamoto, Lucas Ravagnani Silva, Lucas Giansante Abud, Jorge Alberto Martins Pentiado Junior

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thales Pardini FagundesDepartment of Head and Neck / Neurosurgery / Neuro-oncology, Hospital de Câncer de Barretos, Barretos, Brazil. pardinithales@gmail.com.ORCID http://orcid.org/0000-0002-3302-9913
Gustavo Maximiano AlvesSchool of Medicine at Ribeirão Preto, Department of Neuroscience and Behavioural Sciences, Ribeirão Preto, Brazil.
Mateus Gustavo FavaroSchool of Medicine at Ribeirão Preto, Department of Neuroscience and Behavioural Sciences, Ribeirão Preto, Brazil.
Joyce Yuri Silvestre YamamotoSchool of Medicine at Ribeirão Preto, Department of Neuroscience and Behavioural Sciences, Ribeirão Preto, Brazil.
Lucas Ravagnani SilvaSchool of Medicine at Ribeirão Preto, Department of Neuroscience and Behavioural Sciences, Ribeirão Preto, Brazil.
Lucas Giansante AbudHospital São Lucas de Ribeirão Preto, Department of Diagnostic Imaging, Ribeirão Preto, Brazil.
Jorge Alberto Martins Pentiado JuniorPain Center, Department of Neurology, University of São Paulo, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory cerebral amyloid angiopathy (CAA-RI) is a variant of CAA, rarely seen in young individuals with Down syndrome (DS). We describe a 32-year-old female with DS who developed a systemic inflammatory state followed by acute neurological symptoms, including seizures and hemiparesis. Brain MRI disclosed asymmetric T2/FLAIR hyperintensities with leptomeningeal enhancement and focal superficial siderosis on susceptibility-weighted imaging, without microbleeds; cerebrospinal fluid showed marked inflammation. After partial improvement with corticosteroids, rituximab was started due to persistent symptoms. This case highlights CAA-RI as a cause of acute decline in DS and supports the use of rituximab in refractory cases.

Indexed as

Cerebral Amyloid AngiopathyDown SyndromeInflammationAdultBrainFemaleHumansMagnetic Resonance ImagingRituximabRituximabAdultCerebral amyloid angiopathyDown syndromeInflammationRituximab

Identifiers

PMID41677989
PMCPMC12901129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.